RecruitingPhase 1NCT03460977
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Sponsor: Pfizer
Austin, TX · Dallas, TX · +42 more sites
Prostate Cancer clinical trials in Dallas, TX
27 recruiting prostate cancer studies with a site in Dallas, TX.
RecruitingPhase 2NCT05691465
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
Sponsor: National Cancer Institute (NCI)
Dallas, TX · Houston, TX · +11 more sites
RecruitingPhase 3NCT07028853
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Sponsor: Pfizer
Dallas, TX · +124 more sites
RecruitingPhase 1NCT07114601
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Sponsor: Eli Lilly and Company
Dallas, TX · Houston, TX · +14 more sites
RecruitingPhase 3NCT07723248
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
Sponsor: ORIC Pharmaceuticals
Dallas, TX · Fort Worth, TX · Houston, TX · +8 more sites
RecruitingPhase 3NCT06626022
Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.
Sponsor: University of Alberta
Dallas, TX · +1 more sites
RecruitingPhase not listedNCT07124000
DESTINY-PANTUMOUR04
Sponsor: AstraZeneca
Dallas, TX · +17 more sites
RecruitingPhase 3NCT07225946
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Sponsor: Janssen Research & Development, LLC
Austin, TX · Dallas, TX · Houston, TX · +56 more sites
RecruitingPhase 1NCT07277270
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
Sponsor: GlaxoSmithKline
Dallas, TX · +4 more sites
RecruitingPhase 2 / Phase 3NCT06780670
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Sponsor: Novartis Pharmaceuticals
Dallas, TX · San Antonio, TX · +33 more sites
RecruitingPhase 3NCT07213674
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Sponsor: Amgen
Arlington, TX · Dallas, TX · Houston, TX · +42 more sites
RecruitingPhase 1NCT07080242
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Sponsor: SystImmune Inc.
Dallas, TX · Houston, TX · +21 more sites
RecruitingPhase 3NCT06056830
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Sponsor: Clarity Pharmaceuticals Ltd
Austin, TX · Dallas, TX · +26 more sites
RecruitingPhase 1NCT07545811
Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Sponsor: Janux Therapeutics
Dallas, TX · +5 more sites
RecruitingPhase 2NCT05726292
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
Sponsor: University of Chicago
Dallas, TX · +3 more sites
RecruitingPhase 3NCT04423211
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Sponsor: ECOG-ACRIN Cancer Research Group
Dallas, TX · +338 more sites
RecruitingPhase 2NCT06842498
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Sponsor: Kyntra Bio
Dallas, TX · Houston, TX · +21 more sites
RecruitingPhase 3NCT06592924
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Sponsor: Canadian Cancer Trials Group
Baytown, TX · Cypress, TX · Dallas, TX · +371 more sites
RecruitingPhase 1NCT05413421
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Sponsor: ORIC Pharmaceuticals
Amarillo, TX · Dallas, TX · +18 more sites
RecruitingPhase 1NCT07540572
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
Sponsor: IDEAYA Biosciences
Austin, TX · Dallas, TX · Fort Worth, TX · +8 more sites
RecruitingPhase 1 / Phase 2NCT06267729
Study of AZD0754 in Participants With Metastatic Prostate Cancer
Sponsor: AstraZeneca
Dallas, TX · Houston, TX · +11 more sites
RecruitingPhase 4NCT04373564
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Sponsor: Guerbet
Dallas, TX · Houston, TX · +14 more sites
RecruitingPhase not listedNCT06353321
Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1
Sponsor: University of Texas Southwestern Medical Center
Dallas, TX
RecruitingPhase 1NCT06999187
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Sponsor: Dren Bio
Austin, TX · Dallas, TX · San Antonio, TX · +7 more sites
RecruitingPhase 1 / Phase 2NCT05914116
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Sponsor: DualityBio Inc.
Austin, TX · Dallas, TX · +26 more sites
RecruitingPhase not listedNCT05001477
Customized TULSA-PRO Ablation Registry
Sponsor: Profound Medical Inc.
Dallas, TX · San Antonio, TX · +3 more sites
Not yet recruitingEarly Phase 1NCT07674771
Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery
Sponsor: University of Texas Southwestern Medical Center
Dallas, TX
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.